Introduction Patients with type 2 diabetes (T2DM) and chronic kidney disease (CKD) are at
high risk of CKD progression and cardiovascular events. Despite treatment with renin …

Background Finerenone reduced risk of cardiorenal outcomes in patients with CKD and type
2 diabetes in the FIDELIO-DKD trial. We report incidences and risk factors for hyperkalemia …

Persons with diabetes and chronic kidney disease (CKD) have a high residual risk of
developing cardiovascular (CV) complications despite treatment with renin-angiotensin …

Introduction Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has
favourable effects on cardiorenal outcomes in patients with mild‐to‐severe chronic kidney …

Diabetes is the leading cause of chronic and end stage kidney disease globally. Despite
recent advances in therapies for diabetic kidney disease (DKD), there remains a critical …

Objective: To describe the pharmacology, clinical and safety evidence, and relevance to
clinical practice of finerenone. Data Sources: A literature search was conducted utilizing …

Introduction Diabetic kidney disease (DKD) represents a leading cause of morbidity and
mortality in subjects with diabetes and develops in more than one third of diabetic patients …

Recently, a few randomized control trials (RCTs) suggested that finerenone has been shown
to reduce cardiovascular events in patients with CKD and DM-2. We aimed to analyze the …

The nonsteroidal MRA finerenone could improve renal and cardiac outcomes further in
diabetics with kidney disease when added to renin-angiotensin system inhibitors …

Purpose This review provides an overview of the management of chronic kidney disease
(CKD) associated with type 2 diabetes (T2D), how the novel treatment class of nonsteroidal …